Mutational landscape analysis in AML also revealed that TET2 mutations frequently co-occur with other mutations in NPM1, FLT3, JAK2, RUNX1, CEBPA, and KRAS [71], suggesting that TET2 inactivation cooperates with these additional mutations in driving leukemogenesis. This evidence concerns the gene CEBPA and acute myeloid leukemia.